Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology

Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Rohit, Srivastava, M. V. Padma, Khurana, Dheeraj, Pandit, Lekha, Mathew, Thomas, Gupta, Salil, Netravathi, M, Nair, Sruthi S., Singh, Gagandeep, Singhal, Bhim S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
View Point
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213028/
https://www.ncbi.nlm.nih.gov/pubmed/32419748
http://dx.doi.org/10.4103/0972-2327.282442
Descripción
Sumario:Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.

Ejemplares similares